利拉鲁肽对非酒精性脂肪肝大鼠模型疗效评价

目的 采用氢质子磁共振波谱(1H-MRS)、病理及血清指标来评价利拉鲁肽治疗非酒精性脂肪肝(NAFLD)大鼠模型的疗效.方法 清洁级雄性SD大鼠32只,随机分为高脂组20只和正常对照组12只,高脂组造模成功后随机分为利拉鲁肽组和安慰剂组,继续予高脂饮食并分别予皮下注射利拉鲁肽或生理盐水,正常对照组予普通饲料喂养.干预16周末,1H-MRS检测各组大鼠肝脏相对脂肪含量,并行肝组织病理HE染色及生化等指标检测,采用方差齐性检验分析数据.结果 与安慰剂组相比,利拉鲁肽组大鼠体质量、肝指数、胰岛素抵抗指数、血清空腹胰岛素、三酰甘油、胆固醇、低密度脂蛋白、谷丙转氨酶均明显下降(P<0.05);与安慰剂组相比,利拉鲁肽组大鼠肝组织病理及1H-MRS结果示肝脏脂肪变性程度明显减轻甚至恢复正常,肝内相对脂肪含量明显减少(P<0.05).结论 利拉鲁肽能明显减轻高脂饮食诱导的NAFLD大鼠体质量,改善肝指数和肝脏相对脂肪含量,利拉鲁肽有可能成为治疗NAFLD的新药物.

Efficacy of Liraglutide on nonalcoholic fatty liver in rats

Objective Proton magnetic resonance spectroscopy(1H-MRS), pathology and serum index were used to evaluate the efficacy of Liraglutide in the treatment of nonalcoholic fatty liver(NAFLD) rat models.Methods Thirty two male SD rats were selected, and randomly divided into high fat diet group and control group.High fat diet group were fed with high fat diet,then randomly divided into Liraglutide group and placebo group after model were successfully established, and all the rats still were fed with high fat diet and respectively injected with Liraglutide or saline everyday, control group were fed with normal food.After 16 weeks of treatment, the hepatic triglycer-ide content of each rat was detected by 1H-MRS and liver tissue was detected by HE stain and serum index were tested.Results Compared with the placebo group, the body weight, liver index, homeostasis model of assessment for insulin resistance index and fasting insulin, triglyceride, cholesterol, low densith lipoprotein,alanine aminotransferase in the serum of rats were significantly decreased in the Liraglutide group(P<0.05).Compared with placebo group,the result of 1H-MRS and liver tissue in pathological in Liraglutide group showed that liver steatosis was significantly improved,some of them even become normal, the content of fat in liver was decreased(P<0.05).Conclusion Liraglutide can significantly improve the body weight, liver index and decrease the content of liver fat in the rats with NAFLD induced by high fat diet, thus,it possibly can be a promising drug in the treatment of NAFLD.